Drug interactions
Asenapine transdermal + Umeclidinium-vilanterol
Severity: Moderate
Asenapine transdermal and Umeclidinium-vilanterol: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Asenapine has a modest QT-prolonging effect, and vilanterol may add to cardiac repolarization effects. The legacy suggestion of QT shortening is not accurate, but clinically relevant additive risk is limited in most patients.
What this interaction means in plain words
Asenapine transdermal and Umeclidinium-vilanterol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Possible additive QT prolongation and tachycardia.
What to do
Check ECG in patients with cardiac disease or other QT risk factors. Correct electrolyte abnormalities.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Asenapine transdermal and Umeclidinium-vilanterol, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Umeclidinium-vilanterol
Frequently asked questions
Can I take Asenapine transdermal with Umeclidinium-vilanterol?
MediHelp rates the interaction as moderate. Asenapine transdermal and Umeclidinium-vilanterol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Asenapine has a modest QT-prolonging effect, and vilanterol may add to cardiac repolarization effects. The legacy suggestion of QT shortening is not accurate, but clinically relevant additive risk is limited in most patients.
How serious is the interaction between Asenapine transdermal and Umeclidinium-vilanterol?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Check ECG in patients with cardiac disease or other QT risk factors. Correct electrolyte abnormalities.
What other medicines interact with Umeclidinium-vilanterol?
MediHelp also lists interactions of Umeclidinium-vilanterol with, for example, Aclidinium, Amiodarone, Amitriptyline. The full list is on the Umeclidinium-vilanterol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
